Unlock stock picks and a broker-level newsfeed that powers Wall Street.
3.0100
+0.1500
+(5.24%)
At close: 4:00:01 PM EDT
2.9900
-0.02
(-0.66%)
After hours: 5:21:31 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Matthew Pauls J.D., M.B.A. | Chairman & CEO | 970k | -- | 1971 |
| Mr. David L. Lowrance CPA | CFO, Chief Administrative Officer & Secretary | 667.4k | -- | 1968 |
| Mr. Robert Matthew Lutz M.B.A. | Chief Operating Officer | 723.55k | -- | 1969 |
| Ms. Kate McCabe J.D. | Chief Legal Officer | -- | -- | -- |
| Ms. Anne Erickson | Chief Business Officer | -- | -- | 1973 |
| Brian Maurer | Head of Clinical Operations | -- | -- | -- |
| Mr. Charles LaPree | Executive VP & Head of Global Regulatory Affairs | -- | -- | -- |
| Dr. Raymond Dennis Pratt FACP, M.D. | Chief Medical Officer | 91.89k | -- | 1951 |
| Dr. Brian Robinson M.D. | Executive Vice President of Global Medical Affairs | -- | -- | -- |
| Dr. Yasmine Wasfi M.D., Ph.D. | Executive VP and Head of Clinical Development & Clinical Operations | -- | -- | -- |
Savara Inc.
1717 Langhorne Newtown Road
Suite 300
Langhorne, PA 19047
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 59
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
Corporate Governance
Savara Inc.’s ISS Governance QualityScore as of April 1, 2025 is 5. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 1; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 7, 2025 at 10:59 AM UTC - May 12, 2025 at 12:00 PM UTC
Savara Inc. Earnings Date
Recent Events
Related Tickers
THAR Tharimmune, Inc.
1.2900
-1.53%
CMPX Compass Therapeutics, Inc.
1.6900
-24.55%
KROS Keros Therapeutics, Inc.
10.04
+5.13%
PHGE BiomX Inc.
0.6290
+27.59%
AARD Aardvark Therapeutics, Inc. Common Stock
9.35
+12.79%
TECX Tectonic Therapeutic, Inc.
17.89
+6.24%
EWTX Edgewise Therapeutics, Inc.
15.52
-22.90%
TARS Tarsus Pharmaceuticals, Inc.
51.49
+5.25%
VERA Vera Therapeutics, Inc.
23.59
+7.13%
SPRO Spero Therapeutics, Inc.
0.7060
+1.73%